The S100A protein family is a group of EF-hand-type calcium-binding proteins encoded
by genes located in the epidermal differentiation complex that regulates cell structure,
proliferation, and differentiation [
[1]
]. Increased expression of S100A7, also named psoriasin, was first identified in psoriasis
and is known as a useful marker of its disease activity [
2
,
3
,
4
]. S100A7 works as an antimicrobial peptide, chemoattracts immune cells including
neutrophils, and accelerates local inflammation [
[3]
]. The expression of S100A7 is upregulated by various proinflammatory cytokines including
tumor necrosis factor-α (TNF-α) [
[3]
]. Biological treatments such as the anti-TNF-α antibodies adalimumab and infliximab
successfully reduce the lesional expression of S100A7 in psoriasis [
[2]
,
[4]
].To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Dermatological ScienceAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The S100 proteins in epidermis: topology and function.Biochim. Biophys. Acta. 2015; 1850: 2563-2572
- Effects of adalimumab, etanercept and ustekinumab on the expression of psoriasin (S100A7) in psoriatic skin.J. Dermatol. Sci. 2015; 80: 38-44
- S100A7: a rAMPing up AMP molecule in psoriasis.Cytokine Growth Factor Rev. 2016; 32: 97-104
- S100A7 expression levels in coordination with interleukin-8 indicate the clinical response to infliximab for psoriasis patients.J. Dermatol. 2017; 44: 838-839
- The peroxisome proliferator-activated receptor β/δ (PPARβ/δ) agonist GW501516 prevents TNF-α-induced NF-κB activation in human HaCaT cells by reducing p65 acetylation through AMPK and SIRT1.Biochem. Pharmacol. 2011; 81: 534-543
- Protective role of peroxisome proliferator-activated receptor α agonists in skin barrier and inflammation.Immunobiology. 2018; 223: 327-330
- Preclinical studies of a specific pparγ modulator in the control of skin inflammation.J. Invest. Dermatol. 2014; 134: 1001-1011
- PPARalpha activators and fasting induce the expression of adipose differentiation-related protein in liver.J. Lipid Res. 2006; 47: 931-943
- Prevalence of metabolic syndrome among patients with psoriasis treated with TNF inhibitors and the effects of anti-TNF therapy on their lipid profile: a prospective cohort study.Metab. Syndr. Relat. Disord. 2020; (in press)
- Exploration and development of PPAR modulators in health and disease: an update of clinical evidence.Int. J. Mol. Sci. 2019; 20 (pii: E5055)
Article info
Publication history
Published online: May 18, 2020
Accepted:
May 12,
2020
Received in revised form:
April 30,
2020
Received:
March 3,
2020
Identification
Copyright
© 2020 Japanese Society for Investigative Dermatology. Published by Elsevier B.V. All rights reserved.
